The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)
Open accessAbstract
The proteoglycan aggrecan is an important major component of cartilage matrix that gives articular cartilage the ability to withstand compression. Increased breakdown of aggrecan is associated with the development of arthritis and is considered to be catalyzed by aggrecanases, members of the ADAM-TS family of metalloproteinases. Four endogenous tissue inhibitors of metalloproteinases (TIMPs) regulate the activities of functional matrix metalloproteinases (MMPs), enzymes that degrade most components of connective tissue, but no endogenous factors responsible for the regulation of aggrecanases have been found. We show here that the N-terminal inhibitory domain of TIMP-3, a member of the TIMP family that has functional properties distinct from other TIMPs, is a strong inhibitor of human aggrecanases 1 and 2, with K(i) values in the subnanomolar range. This truncated inhibitor, which lacks the C-terminal domain that is responsible for interactions with molecules other than active metalloproteinases, is produced at high yield by bacterial expression and folding from inclusion bodies. This provides a starting point for developing a biologically available aggrecanase inhibitor suitable for the treatment of arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagase, H., & Woessner, J. F. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21491 · Cited by 3,912
Self-citationTissue inhibitors of metalloproteinases: evolution, structure and function
Brew, K., Dinakarpandian, D., & Nagase, H. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00279-4 · Cited by 1,908
Self-citationThe Behavior and Significance of Slow‐Binding Enzyme Inhibitors
Morrison, J. F., & Walsh, C. T. (1988) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470123072.ch5 · Cited by 840
Purification and Cloning of Aggrecanase-1: A Member of the ADAMTS Family of Proteins
Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. M., Liu, R., Rosenfeld, S. A., Copeland, R. A., Decicco, C. P., Wynn, R., et al. (1999) · Science · doi:10.1126/science.284.5420.1664 · Cited by 686
Self-citationProteinpolysaccharide Complex from Bovine Nasal Cartilage
Hascall, V., & Sajdera, S. W. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78236-2 · Cited by 668
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.
Gomis-R¨th, F.-X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkov, G. P., et al. (1997) · Nature · doi:10.1038/37995 · Cited by 619
Self-citationTNF‐α converting enzyme (TACE) is inhibited by TIMP‐3
Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knäuper, V., et al. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01031-x · Cited by 609
Cloning and Characterization of ADAMTS11 , an Aggrecanase from the ADAMTS Family
Abbaszade, I., Liu, R.-Q., Yang, F., Rosenfeld, S. A., Ross, O. H., Link, J. R., Ellis, D. M., Tortorella, M. D., Pratta, M. A., Hollis, J. M., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.33.23443 · Cited by 490
Self-citationLark, M. W., Bayne, E. K., Flanagan, J., Harper, C. F., Hoerrner, L. A., Hutchinson, N. I., Singer, I. I., Donatelli, S. A., Weidner, J. R., Williams, H. R., et al. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119526 · Cited by 470
Baker, A. H., Zaltsman, A. B., George, S. J., & Newby, A. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1584 · Cited by 464
Cited by
Visse, R., & Nagase, H. (2003) · Circulation Research · doi:10.1161/01.res.0000070112.80711.3d · Cited by 4,575
Self-citationHow Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
“TIMP3 is also unique in its ability to inhibit ADAMs-10 and -17, ADAMTS-4, and ADAMTS-5 (Kashiwagi et al. 2001), whereas TIMP1 can inhibit ADAMTS-1 (Tortorella et al. 1999).”
BackgroundBrew, K., & Nagase, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.01.003 · Cited by 1,381
Self-citationStrategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
Baker, A. H., Edwards, D. R., & Murphy, G. (2002) · Journal of Cell Science · doi:10.1242/jcs.00063 · Cited by 1,179
The ADAMs family of metalloproteases: multidomain proteins with multiple functions
Seals, D. F., & Courtneidge, S. A. (2003) · Genes & Development · doi:10.1101/gad.1039703 · Cited by 1,059
PORTER, S., CLARK, I. M., KEVORKIAN, L., & EDWARDS, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20040424 · Cited by 779
Progress in matrix metalloproteinase research
MURPHY, G., & NAGASE, H. (2008) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2008.05.002 · Cited by 759
Self-citationMatrix Metalloproteinases, Vascular Remodeling, and Vascular Disease
Wang, X., & Khalil, R. A. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.08.002 · Cited by 754
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease
Raffetto, J. D., & Khalil, R. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.004 · Cited by 752
Metalloproteinases and their inhibitors: Regulators of wound healing
Gill, S. E., & Parks, W. C. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.10.024 · Cited by 742
The role of TIMPs in regulation of extracellular matrix proteolysis
Arpino, V., Brock, M., & Gill, S. E. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.03.005 · Cited by 734
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies
Folgueras, A. R., Pendas, A. M., Sanchez, L. M., & Lopez-Otin, C. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041811af · Cited by 590
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Self-citationLambert, E., Dassé, E., Haye, B., & Petitfrère, E. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.008 · Cited by 541
Ovulation: Parallels With Inflammatory Processes
Duffy, D. M., Ko, C., Jo, M., Brannstrom, M., & Curry, T. E. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00075 · Cited by 513
Apte, S. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.052340 · Cited by 506
Tissue inhibitors of metalloproteinases
Murphy, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-11-233 · Cited by 472
Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc
Le Maitre, C. L., Freemont, A. J., & Hoyland, J. A. (2004) · The Journal of Pathology · doi:10.1002/path.1608 · Cited by 443
Vo, N. V., Hartman, R. A., Yurube, T., Jacobs, L. J., Sowa, G. A., & Kang, J. D. (2013) · The Spine Journal · doi:10.1016/j.spinee.2012.02.027 · Cited by 433
Bondeson, J., Blom, A. B., Wainwright, S., Hughes, C., Caterson, B., & van den Berg, W. B. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27290 · Cited by 419
Altered Proteolytic Activities of ADAMTS-4 Expressed by C-terminal Processing
Kashiwagi, M., Enghild, J. J., Gendron, C., Hughes, C., Caterson, B., Itoh, Y., & Nagase, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312123200 · Cited by 409
Self-citationExpression profiling of metalloproteinases and their inhibitors in cartilage
Kevorkian, L., Young, D. A., Darrah, C., Donell, S. T., Shepstone, L., Porter, S., Brockbank, S. M. V., Edwards, D. R., Parker, A. E., & Clark, I. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11433 · Cited by 404
The Basic Science of Tendinopathy
Xu, Y., & Murrell, G. A. C. (2008) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-008-0286-4 · Cited by 346
Structural aspects of the metzincin clan of metalloendopeptidases
Gomis-Rüth, F. X. (2003) · Molecular Biotechnology · doi:10.1385/mb:24:2:157 · Cited by 340
Proteoglycans in health and disease: the multiple roles of syndecan shedding
Manon‐Jensen, T., Itoh, Y., & Couchman, J. R. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07798.x · Cited by 337
Mechanical loading, cartilage degradation, and arthritis
Sun, H. B. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05808.x · Cited by 335
Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
Raeeszadeh-Sarmazdeh, M., Do, L., & Hritz, B. (2020) · Cells · doi:10.3390/cells9051313 · Cited by 324
Sacitharan, P. K. (2019) · Subcellular Biochemistry · doi:10.1007/978-981-13-3681-2_6 · Cited by 308
Metalloproteinases and their inhibitors in tumor angiogenesis
Handsley, M. M., & Edwards, D. R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20945 · Cited by 307
Jones, G. C., Corps, A. N., Pennington, C. J., Clark, I. M., Edwards, D. R., Bradley, M. M., Hazleman, B. L., & Riley, G. P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21672 · Cited by 292
Pharmacologic therapy for osteoarthritis—the era of disease modification
Hunter, D. J. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.178 · Cited by 288
BMP1 controls TGFβ1 activation via cleavage of latent TGFβ-binding protein
Ge, G., & Greenspan, D. S. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200606058 · Cited by 275
Pockert, A. J., Richardson, S. M., Le Maitre, C. L., Lyon, M., Deakin, J. A., Buttle, D. J., Freemont, A. J., & Hoyland, J. A. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24291 · Cited by 273
Emerging roles of ADAM and ADAMTS metalloproteinases in cancer
Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J. M., Noel, A., & Cataldo, D. (2008) · Biochimie · doi:10.1016/j.biochi.2007.08.008 · Cited by 266
Endocardial Brg1 Represses ADAMTS1 to Maintain the Microenvironment for Myocardial Morphogenesis
Stankunas, K., Hang, C. T., Tsun, Z.-Y., Chen, H., Lee, N. V., Wu, J. I., Shang, C., Bayle, J. H., Shou, W., Iruela-Arispe, M. L., et al. (2008) · Developmental Cell · doi:10.1016/j.devcel.2007.11.018 · Cited by 262
Apte, S. S. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.01.014 · Cited by 261
miR-191: an emerging player in disease biology
Nagpal, N., & Kulshreshtha, R. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00099 · Cited by 168
Individual Timp Deficiencies Differentially Impact Pro-MMP-2 Activation
English, J. L., Kassiri, Z., Koskivirta, I., Atkinson, S. J., Di Grappa, M., Soloway, P. D., Nagase, H., Vuorio, E., Murphy, G., & Khokha, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512009200 · Cited by 120
Self-citationZhong, S., & Khalil, R. A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.033 · Cited by 119
Nandadasa, S., Kraft, C. M., Wang, L. W., O’Donnell, A., Patel, R., Gee, H. Y., Grobe, K., Cox, T. C., Hildebrandt, F., & Apte, S. S. (2019) · Nature Communications · doi:10.1038/s41467-019-08520-7 · Cited by 76
Sorsby fundus dystrophy—A review of pathology and disease mechanisms
Christensen, D. R. G., Brown, F. E., Cree, A. J., Ratnayaka, J. A., & Lotery, A. J. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.08.014 · Cited by 60
Pattoli, M. A., MacMaster, J. F., Gregor, K. R., & Burke, J. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087569 · Cited by 56
“…that whereas MMP-1 and MMP-13 production is NF- B-dependent, the production of the TIMP-1 (an endogenous inhibitor of MMP) and TIMP-3 (an important inhibitor of ADAMTS-4 and ADAMTS-5; see Kashiwagi et al., 2001; Gendron et al., 2003) in SW-1353 chondrocytes appears to be largely NF- B-independent.”
BackgroundSelvais, C., Gaide Chevronnay, H. P., Lemoine, P., Dedieu, S., Henriet, P., Courtoy, P. J., Marbaix, E., & Emonard, H. (2009) · Endocrinology · doi:10.1210/en.2009-0015 · Cited by 54
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.
Rapti, M., Atkinson, S. J., Lee, M.-H., Trim, A., Moss, M., & Murphy, G. (2008) · Biochemical Journal · doi:10.1042/bj20071430 · Cited by 43
A microarray study to characterize the molecular mechanism of TIMP-3-mediated tumor rejection
Lam, P., Sian Lim, K., Mei Wang, S., & Hui, K. M. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.02.028 · Cited by 22
Metadata
- Authors
- Kashiwagi, M., Tortorella, M., Nagase, H., & Brew, K.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-04
- Volume
- 276
- Issue
- 16
- Pages
- 12501-12504
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2093394571
- Cited by
- 509
- References
- 36
- FWCI
- 10.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.